People: Clovis Oncology Inc (CLVS.O)

CLVS.O on Nasdaq

38.68USD
11 Jul 2014
Price Change (% chg)

$0.25 (+0.65%)
Prev Close
$38.43
Open
$38.35
Day's High
$38.77
Day's Low
$37.36
Volume
393,894
Avg. Vol
942,802
52-wk High
$93.33
52-wk Low
$36.11

Search Stocks

Barrett, M. James 

Brief Biography

Dr. M. James Barrett, Ph.D., is an Independent Chairman of the Board of Clovis Oncology, Inc since inception, April 20, 2009. Since September 2001, he has served as a general partner of New Enterprise Associates Inc., a venture capital firm focusing on the healthcare, information technology and energy technology industries. From 1997 to 2001, Dr. Barrett served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, which he founded in 1997. Dr. Barrett serves on the boards of several pharmaceutical and biotechnology companies, including Amicus Therapeutics, Inc. (NASDAQ: FOLD), Blend Biosciences, Inc., Cardioxyl Pharmaceuticals, Inc., Galera Therapeutics, Inc., GlycoMimetics, Inc. (NASDAQ: GLYC), PhaseBio Pharmaceuticals, Inc., Predictive Biosciences, Inc., Psyadon Pharmaceuticals, Inc. (formerly known as Ruxton Pharmaceuticals, Inc.), Roka Bioscience, Inc., Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), and ZP Holdings, Inc., as well as continuing to serve as Chairman of Sensors for Medicine and Science. Dr. Barrett previously served on the board of, among others, Inhibitex, Inc. (NASDAQ: INHX) (acquired by Bristol-Myers Squibb (NASDAQ: BMY)), Targacept, Inc. (NASDAQ: TRGT), Pharmion Corporation, and YM Biosciences, Inc. (AMEX: YMI). Dr. Barrett received a Ph.D. in biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in chemistry from Boston College. We believe that Dr. Barrett possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the venture capital industry and his years of business and leadership experience.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. James Barrett

--

Patrick Mahaffy

3,655,580

Erle Mast

1,625,970

Andrew Allen

1,668,940

Gillian Ivers-Read

1,636,860

Steven Hoerter

1,329,380
As Of 30 Dec 2013
Search Stocks